Regional chemotherapy in biliary tract cancers - A single institution experience

Hepato-Gastroenterology

Volumn 49, Issue 46, 2002, Pages 900-906

  Melichar, Bohuslav ^a   Cerman Jr , Jaroslav ^a   Dvorák, Josef ^a   Jandík, Pavel ^a   Mergancová, Jindríska ^a   Melicharová, Karolina ^a   Tousková, Miroslava ^a   Krajina, Antonín ^a   Voboril, Zbynék ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Gallbladder carcinoma; Regional chemstherapy

Indexed keywords

ALPHA INTERFERON; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; TEGAFUR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; BILIARY TRACT TUMOR; COHORT ANALYSIS; CZECH REPUBLIC; EVALUATION; FOLLOW UP; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CZECH REPUBLIC; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMAN; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LYMPHOCYTE COUNT; MALE; MIDDLE AGE; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; HUMANS; MIDDLE AGED;

EID: 0036021304     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Biliary tract cancers
2. Uncommon hepatobiliary tumors
3. Resectional surgery of hilar cholangiocarcinoma: A multivariate analysis of prognostic factors
4. Liver transplantation for cholangiocarcinoma: Results in 207 patients
5. Superselective intra-arterial chemotherapy with mitomycin for gallbladder cancer
6. Phase II trial of intravenous fluorouracil and subcutaneous interferon-alfa2b for biliary tract cancer
7. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
8. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
9. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery
10. The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature
11. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas
12. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors
13. Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases
14. Outcome of treatment for distal bile duct cancer
15. Long-term surival of young woman with peripheral cholangiocarcinoma: A case report
16. Hepatic arterial infusion chemotherapy of cisplatin for biliary cystadenocarcinoma
17. Induction chemotherapy via hepatic artery for gallbladder carcinoma
18. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern cooperative oncology group trial
19. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers
20. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: Multicenter randomized trial
21. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: A practical management guideline
22. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage
23. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients
24. Chemotherapy improves survival and quality of live in advanced pancreatic and biliary cancer
25. Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan - Experience of a single institute
26. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival
27. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma
28. Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies
29. Effects of anticancer drugs on the immune system in humans
30. The peripheral blood leukocyte phenotype in patients with breast cancer: Effect of doxorubicin/paclitaxel combination chemotherapy
31. Cancer vaccines: Reborn or just recycled?
32. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver
33. "Natural history" of unresected cholangiocarcinoma: Patient outcome after noncurative intervention
34. Prognosis and treatment of bile duct carcinoma
35. Biliary tree malignancies: The University of Minnesota experience
36. Clinical experience in 126 patients with tissue-proved proximal cholangiocarcinoma
37. Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival
38. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma
39. Peripheral cholangiocarcinoma: Presentation, diagnosis, pathology and management
40. Radical surgery for gallbladder cancer: A worthwhile operation?
41. Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer
42. Chemotherapy of biliary tract cancer with mitomycin C and 5-fluorouracil biologically modulated by folinic acid. A phase II study
43. A phase II study of cisplatin in patients with biliary tract carcinoma
44. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas
45. Gemcitabine for the treatment of advanced biliary tract carcinomas: Evaluation of two different dose regimens